IN BRIEF: ImmuPharma forecasts 'year of delivery' in 2026
ImmuPharma PLC - London-based specialist drug discovery and development company - Chair Tim McCarthy produces open letter to shareholders, noting that resolutions relating to the proposed £6 million Lanstead subscription and £468,000 WRAP retail offer were approved at the general meeting. Says the fundraise ‘significantly strengthens our balance sheet and provides the capital required to advance our key strategic priorities.’ McCarthy adds that ImmuPharma’s primary focus remains securing a value-enhancing partnering agreement for lead auto-immune technology platform, P140, this year, as recent progress ‘continues to reinforce both [its] scientific rationale and commercial positioning,’ and management is ‘actively engaged in progressing discussions toward this objective’. ImmuPharma is also investing in its ‘second key asset’, type 1 diabetes treatment Kapiglucagon. Says the structure of the Lanstead subscription provides a mechanism to potentially benefit from future share price performance, with an 8 pence benchmark acting as the reference point for returns, meaning that progress on P140 and Kapiglucagon could ‘support value creation over the period of the [sharing] agreement.’
‘Importantly, the successful fundraising extends the company’s cash runway to at least H2 2028,’ McCarthy says. ‘This strong financial leverage enhances our ability to negotiate a P140 licensing agreement from a position of strength, while also providing the flexibility to accelerate the Kapiglucagon program and selectively invest in earlier-stage pipeline opportunities. With the progress already underway, the Board believes 2026 will be a year of delivery, momentum, and success for ImmuPharma and its shareholders.’
Current stock price: 5.04p, up 8.4% in London on Thursday
12-month change: more than doubled from 2.15p
Copyright 2026 Alliance News Ltd. All Rights Reserved.